{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:41:16Z","timestamp":1792363276748,"version":"4.4.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.beem.2022.101635","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T11:52:01Z","timestamp":1646049121000},"page":"101635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy"],"prefix":"10.1016","volume":"36","author":[{"given":"M.","family":"Atkinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Lansdown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.beem.2022.101635_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.beem.2022.101635_bib2","series-title":"Emergency management of acute adrenal insufficiency (adrenal crisis) in adult patients. Bioscientifica Ltd Euro house, 22 Apex court woodlands","first-page":"G1","author":"Arlt","year":"2016"},{"issue":"3","key":"10.1016\/j.beem.2022.101635_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A\u00a0systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"De Filette","year":"2019","journal-title":"Horm Metab Res"},{"issue":"12","key":"10.1016\/j.beem.2022.101635_bib4","doi-asserted-by":"crossref","first-page":"T331","DOI":"10.1530\/ERC-17-0358","article-title":"Endocrine side effects of cancer immunotherapy","volume":"24","author":"Cukier","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1016\/j.beem.2022.101635_bib5","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J\u00a0Immuno Ther Cancer"},{"issue":"2","key":"10.1016\/j.beem.2022.101635_bib6","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERC-18-0320","article-title":"French Endocrine Society Guidance on endocrine side effects of immunotherapy","volume":"26","author":"Castinetti","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2022.101635_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.beem.2022.101635_bib8","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1634\/theoncologist.2019-0555","article-title":"Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO VigiBase report analysis","volume":"25","author":"Grouthier","year":"2020","journal-title":"Oncol"},{"issue":"1","key":"10.1016\/j.beem.2022.101635_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40842-018-0073-4","article-title":"Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports","volume":"5","author":"Tan","year":"2019","journal-title":"Clin Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2022.101635_bib10","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1210\/js.2017-00170","article-title":"Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma","volume":"1","author":"Paepegaey","year":"2017","journal-title":"J\u00a0Endocr Soc"},{"issue":"3","key":"10.1016\/j.beem.2022.101635_bib11","first-page":"232","article-title":"Primary adrenal insufficiency from immune checkpoint inhibitors","volume":"4","author":"Shariff","year":"2018","journal-title":"AACE Clin Case Rep"},{"key":"10.1016\/j.beem.2022.101635_bib12","article-title":"A\u00a0case of cancer-associated hyponatraemia: primary adrenal insufficiency secondary to nivolumab","author":"Galliazzo","year":"2021","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"2","key":"10.1016\/j.beem.2022.101635_bib13","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1210\/js.2018-00366","article-title":"Immune checkpoint blockade anti\u2013PD-L1 as a trigger for autoimmune Polyendocrine syndrome","volume":"3","author":"Lanzolla","year":"2019","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.beem.2022.101635_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2018.04.001","article-title":"Immunotherapy-induced Addison's disease: a rare, persistent and potentially lethal side-effect","volume":"97","author":"Hescot","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.beem.2022.101635_bib15","doi-asserted-by":"crossref","first-page":"107050","DOI":"10.1016\/j.intimp.2020.107050","article-title":"Reversible primary adrenal insufficiency related to anti-programmed cell-death 1 protein active immunotherapy: insight into an unforeseen outcome of a rare immune-related adverse event","volume":"89","author":"Deligiorgi","year":"2020","journal-title":"Int Immunopharm"},{"issue":"1","key":"10.1016\/j.beem.2022.101635_bib16","article-title":"Hyponatraemia secondary to nivolumab-induced primary adrenal failure","volume":"2016","author":"Trainer","year":"2016","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"3","key":"10.1016\/j.beem.2022.101635_bib17","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2213-8587(13)70031-7","article-title":"Ipilimumab-induced autoimmune adrenalitis","volume":"1","author":"Min","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2022.101635_bib18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000491631","article-title":"Acute kidney injury after pembrolizumab-induced adrenalitis and adrenal insufficiency","volume":"8","author":"Hanna","year":"2018","journal-title":"Case Rep Nephrol Dial"},{"issue":"4","key":"10.1016\/j.beem.2022.101635_bib19","first-page":"e249","article-title":"Primary adrenal insufficiency and acute cardiomyopathy in a patient with colorectal cancer treated with dual immune checkpoint inhibitors","volume":"20","author":"Kojadinovic","year":"2021","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.beem.2022.101635_bib20","article-title":"Lambert-Eaton myasthenic syndrome secondary to nivolumab and ipilimumab in a patient with small-cell lung cancer","volume":"2019","author":"Agrawal","year":"2019","journal-title":"Case Rep Neurol Med"},{"issue":"1","key":"10.1016\/j.beem.2022.101635_bib21","first-page":"1","article-title":"Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature","volume":"7","author":"Gunjur","year":"2019","journal-title":"J\u00a0Immuno Ther Cancer"},{"issue":"2","key":"10.1016\/j.beem.2022.101635_bib22","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.anl.2019.05.009","article-title":"Adrenal insufficiency following nivolumab therapy in patients with recurrent or metastatic head and neck cancer","volume":"47","author":"Kagoshima","year":"2020","journal-title":"Auris Nasus Larynx"},{"issue":"2","key":"10.1016\/j.beem.2022.101635_bib23","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1159\/000507652","article-title":"Primary adrenal insufficiency during immune checkpoint inhibitor treatment: case reports and review of the literature","volume":"13","author":"Salinas","year":"2020","journal-title":"Case Rep Oncol"},{"issue":"suppl 1","key":"10.1016\/j.beem.2022.101635_bib24","article-title":"Can't cope with the stress of nivolumab therapy: immune mediated adrenal insufficiency","volume":"11","author":"Grenier","year":"2016","journal-title":"J\u00a0Hosp Med"},{"issue":"4","key":"10.1016\/j.beem.2022.101635_bib25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.tjem.2017.05.007","article-title":"Nivolumab, a new immunomodulatory drug, a new adverse effect; adrenal crisis","volume":"17","author":"Akarca","year":"2017","journal-title":"Turk J Emerg Med"},{"issue":"11","key":"10.1016\/j.beem.2022.101635_bib26","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1097\/RLU.0000000000000887","article-title":"Ipilimumab-induced adrenalitis: a possible pitfall in 18F-FDG-PET\/CT","volume":"40","author":"Bacanovic","year":"2015","journal-title":"Clin Nucl Med"},{"issue":"2","key":"10.1016\/j.beem.2022.101635_bib27","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.7861\/clinmed.2020-0827","article-title":"Endocrine complications of immunotherapies: a review","volume":"21","author":"Hattersley","year":"2021","journal-title":"Clin Med"},{"issue":"2","key":"10.1016\/j.beem.2022.101635_bib28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.beem.2022.101635_bib29","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with anti\u2013PD-1 therapy for advanced non\u2013small cell lung cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.beem.2022.101635_bib30","volume":"4","year":"2009"},{"key":"10.1016\/j.beem.2022.101635_bib31","series-title":"Acute Oncology initial management guidelines","year":"2018"},{"issue":"4","key":"10.1016\/j.beem.2022.101635_bib32","doi-asserted-by":"crossref","first-page":"371","DOI":"10.7861\/clinmed.2019-0324","article-title":"Guidance for the prevention and emergency management of adult patients with adrenal insufficiency","volume":"20","author":"Simpson","year":"2020","journal-title":"Clin Med"},{"issue":"17","key":"10.1016\/j.beem.2022.101635_bib33","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.beem.2022.101635_bib34","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S1470-2045(21)00305-3","article-title":"Endocrinopathies induced by immune checkpoint inhibitors: the need for clear endocrine diagnosis","volume":"22","author":"Percik","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beem.2022.101635_bib35","first-page":"1","article-title":"Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors","author":"Zhong","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"10.1016\/j.beem.2022.101635_bib36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000511999","article-title":"The role of immune-related adverse events in prognosis and efficacy prediction for patients with non-small cell lung cancer treated with immunotherapy: a retrospective clinical analysis","volume":"99","author":"Sonehara","year":"2021","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.beem.2022.101635_bib37","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.beem.2022.101635_bib38","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S2213-8587(20)30149-2","article-title":"Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection","volume":"8","author":"Isidori","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2022.101635_bib39","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.mehy.2004.04.009","article-title":"Molecular mimicry of ACTH in SARS\u2013implications for corticosteroid treatment and prophylaxis","volume":"63","author":"Wheatland","year":"2004","journal-title":"Med Hypotheses"},{"issue":"10241","key":"10.1016\/j.beem.2022.101635_bib40","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2022.101635_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.246","article-title":"Rethinking the management of immune checkpoint inhibitor-related adrenal insufficiency in cancer patients during the COVID-19 pandemic","author":"Yuen","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.beem.2022.101635_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.705214","article-title":"Management of patients with glucocorticoid-related diseases and COVID-19","volume":"12","author":"Chifu","year":"2021","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2022.101635_bib43","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.4269\/ajtmh.20-0787","article-title":"Case report: adrenal pathology findings in severe COVID-19: an autopsy study","volume":"103","author":"Santana","year":"2020","journal-title":"Am J Trop Med Hyg"},{"issue":"7","key":"10.1016\/j.beem.2022.101635_bib44","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40618-020-01276-8","article-title":"COVID-19 and the endocrine system: exploring the unexplored","volume":"43","author":"Pal","year":"2020","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2022.101635_bib45","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1590\/2359-3997000000221","article-title":"Hypoparathyroidism and pseudohypoparathyroidism: etiology, laboratory features and complications","volume":"60","author":"Lopes","year":"2016","journal-title":"Arch Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2022.101635_bib46","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.beem.2022.101635_bib47","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1210\/clinem\/dgaa092","article-title":"Activating antibodies to the calcium-sesnsing receptor in immunotherapy-induced hypoparathyroidism","volume":"105","author":"Lupi","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2022.101635_bib48","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/jc.2018-01151","article-title":"Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies","volume":"104","author":"Piranavan","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2022.101635_bib49","first-page":"1","article-title":"Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma","volume":"7","author":"Trinh","year":"2019","journal-title":"J\u00a0Immuno Ther Cancer"},{"issue":"2","key":"10.1016\/j.beem.2022.101635_bib50","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-15-0628","article-title":"European society of endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults","volume":"173","author":"Bollerslev","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2022.101635_bib51","first-page":"23","article-title":"Pembrolizumab-associated hypoparathyroidism: a single case report","volume":"7","author":"Mahmood","year":"2021","journal-title":"AACE Clin Case Rep"},{"issue":"7","key":"10.1016\/j.beem.2022.101635_bib52","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.ajem.2017.02.048","article-title":"Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism","volume":"35","author":"Win","year":"2017","journal-title":"Am J Emerg Med"},{"issue":"7","key":"10.1016\/j.beem.2022.101635_bib53","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1200\/JOP.18.00076","article-title":"Autoimmune-related primary hypoparathyroidism possibly induced by the administration of pembrolizumab: a case report","volume":"14","author":"Umeguchi","year":"2018","journal-title":"J\u00a0Oncol Pract"},{"issue":"2","key":"10.1016\/j.beem.2022.101635_bib54","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1210\/jc.2017-01905","article-title":"Anti\u2013PD-L1 treatment induced central diabetes insipidus","volume":"103","author":"Zhao","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101635_bib55","first-page":"483","article-title":"Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy","volume":"64","author":"Brilli","year":"2020","journal-title":"Arch Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2022.101635_bib56","article-title":"Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies","volume":"2018","author":"Gunawan","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"15","key":"10.1016\/j.beem.2022.101635_bib57","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/imt-2020-0334","article-title":"Anti-PD-1 treatment-induced immediate central diabetes insipidus: a case report","volume":"13","author":"Yu","year":"2021","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.beem.2022.101635_bib58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: a serious immune related adverse event across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"issue":"11","key":"10.1016\/j.beem.2022.101635_bib59","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.beem.2022.101635_bib60","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.6004\/jnccn.2014.0105","article-title":"Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash","volume":"12","author":"Nallapaneni","year":"2014","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"key":"10.1016\/j.beem.2022.101635_bib61","doi-asserted-by":"crossref","first-page":"106427","DOI":"10.1016\/j.intimp.2020.106427","article-title":"Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy","volume":"83","author":"Deligiorgi","year":"2020","journal-title":"Int Immunopharm"},{"issue":"12","key":"10.1016\/j.beem.2022.101635_bib62","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMra1713301","article-title":"Autoimmune polyendocrine syndromes","volume":"378","author":"Husebye","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.beem.2022.101635_bib63","first-page":"1","article-title":"Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy","volume":"4","author":"Lowe","year":"2016","journal-title":"J\u00a0Immuno Ther Cancer"},{"issue":"1","key":"10.1016\/j.beem.2022.101635_bib64","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1620\/tjem.244.33","article-title":"Painless thyroiditis and fulminant type 1 diabetes mellitus in a patient treated with an immune checkpoint inhibitor, nivolumab","volume":"244","author":"Sakurai","year":"2018","journal-title":"Tohoku J Exp Med"},{"issue":"1","key":"10.1016\/j.beem.2022.101635_bib65","article-title":"A\u00a0case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma","volume":"2019","author":"Hakami","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"1","key":"10.1016\/j.beem.2022.101635_bib66","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000456540","article-title":"Autoimmune diabetes and thyroiditis complicating treatment with nivolumab","volume":"10","author":"Li","year":"2017","journal-title":"Case Rep Oncol"},{"issue":"4","key":"10.1016\/j.beem.2022.101635_bib67","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.beem.2022.101635_bib68","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diabet.2016.05.007","article-title":"Autoimmune diabetes superimposed on type 2 diabetes in a patient initiated on immunotherapy for lung cancer","volume":"43","author":"Alhusseini","year":"2017","journal-title":"Diabetes Metabol"},{"issue":"5","key":"10.1016\/j.beem.2022.101635_bib69","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00592-016-0872-y","article-title":"Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes","volume":"53","author":"Kong","year":"2016","journal-title":"Acta Diabetol"},{"issue":"6","key":"10.1016\/j.beem.2022.101635_bib70","first-page":"765","article-title":"A\u00a0case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome. Cancer Immunology","volume":"65","author":"Hansen","year":"2016","journal-title":"Immunotherapy"},{"issue":"8","key":"10.1016\/j.beem.2022.101635_bib71","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1210\/jc.2018-02221","article-title":"Acquired lipodystrophy associated with nivolumab in a patient with advanced renal cell carcinoma","volume":"104","author":"Falcao","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.beem.2022.101635_bib72","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.2337\/dc18-2535","article-title":"Acquired generalized lipodystrophy: a new cause of anti-PD-1 immune-related diabetes","volume":"42","author":"Jehl","year":"2019","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.beem.2022.101635_bib73","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bjd.18124","article-title":"Acquired generalized lipodystrophy under immune checkpoint inhibition","volume":"182","author":"Haddad","year":"2020","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.beem.2022.101635_bib74","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/CMR.0000000000000660","article-title":"Acquired lipodystrophy associated with immune checkpoint inhibitors","volume":"30","author":"Gnanendran","year":"2020","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1016\/j.beem.2022.101635_bib75","first-page":"e40","article-title":"A\u00a0case of acquired generalized lipodystrophy associated with pembrolizumab in a patient with metastatic malignant melanoma","volume":"6","author":"Bedrose","year":"2020","journal-title":"AACE Clin Case Rep"},{"issue":"6","key":"10.1016\/j.beem.2022.101635_bib76","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/CMR.0000000000000405","article-title":"Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination","volume":"27","author":"Lupu","year":"2017","journal-title":"Melanoma Res"},{"issue":"7","key":"10.1016\/j.beem.2022.101635_bib77","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EC-18-0068","article-title":"Society for endocrinology endocrine emergency guidance: acute management of the endocrine complications of checkpoint inhibitor therapy","volume":"7","author":"Higham","year":"2018","journal-title":"Endocr Connect"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:58:22Z","timestamp":1761497902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X22000227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1521690X22000227"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2022.101635","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2022.101635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101635"}}